Targeted Oncology: FDA Grants Orphan Drug Designation to Tovecimig for Biliary Tract Cancer The FDA has granted Orphan Drug Designation to tovecimig (CTX-009) for the treatment of patients with biliary tract cancer (BTC) according to Compass Therapeutics, the company developing the ... MarketWatch: Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer Cancer Therapy Advisor: Time Toxicity Similar in Advanced Biliary Tract Cancer Regardless of First-Line Therapy Received Time Toxicity Similar in Advanced Biliary Tract Cancer Regardless of First-Line Therapy Received Yahoo Finance: Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight LAS VEGAS, /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of ...
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Monthly Prescribing Reference: Tovecimig Plus Paclitaxel Shows Promise in Advanced Biliary Tract Cancer The American Journal of Managed Care: FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
